VXRT - Vaxart: A Strong Buy For Their Oral Tablet Covid-19 Vaccine

• Vaxart, an oral tablet vaccine developer, has initiated and dosed the first participants in their phase 1 trial for COVID-19.
• Although later in development, Vaxart's oral tablet vaccine presents significant advantages in manufacture, distribution and ease-of- administration that may contribute to a much more successful vaccination campaign, if successfully developed.
• Vaxart is a Buy for investors who have the right risk tolerance for a highly speculative, high risk and higher reward investment opportunity.

For further details see: